INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
May 12, 2020 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 19,982 | $569.52 | 549,258 |
Aug 14, 2015 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Open market or private sale of non-derivative or derivative security | 1,405 | $569.63 | 37,901 |
Apr 20, 2020 |
EVP General Counsel and Secret
Trans History: 181
|
EVP General Counsel and Secret | Form 4 | Open market or private sale of non-derivative or derivative security | 125 | $570.27 | 15,188 |
May 11, 2020 |
EVP Research and Development
Trans History: 660
|
EVP Research and Development | Form 4 | Open market or private sale of non-derivative or derivative security | 2,026 | $570.28 | 11,380 |
May 12, 2020 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 20,267 | $570.49 | 528,991 |
May 21, 2020 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Open market or private sale of non-derivative or derivative security | 2,049 | $570.60 | 320,809 |
Aug 14, 2015 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Open market or private sale of non-derivative or derivative security | 3,603 | $570.63 | 34,298 |
Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 6,330 | $570.67 | 569,663 |
May 20, 2020 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 39,974 | $570.97 | 345,084 |
May 20, 2020 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 39,974 | $570.97 | 382,419 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.